Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

Trial Profile

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms STAR-RA; STAR-RA-Cancer
  • Most Recent Events

    • 17 Jun 2022 Status changed from active, no longer recruiting to completed.
    • 29 May 2022 Results published in the Arthritis and Rheumatology
    • 09 Nov 2021 Results assessing safety (risk of malignancy) of tofacitinib in patients with rheumatoid arthritis in real-world settings, presented at the ACR Convergence 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top